WHO Technology Transfer Initiative: supporting grantees through the next phase
|
|
- Nelson Chandler
- 7 years ago
- Views:
Transcription
1 7th Meeting with International Partners on Prospects for Influenza Vaccine Technology Transfer to Developing Country Vaccine Manufacturers WHO Technology Transfer Initiative: supporting grantees through the next phase G. Torelli, WHO, 5 March 0
2 WHAT HAS HAPPENED SINCE THE LAST MEETING in 0 SI PANDEMIC VACCINES APPROVED Green Flu S Vacina Influenza NASOVAC Nasovac-S FLUBIO Enzavac CANTGRIP FLU VAC Green Flu S+ TWO PANDEMIC VACCINES PREUALIFIED TWO SEASONAL VACCINES APPROVED THREE MORE being completed PRODUCTION FACILITIES LAIV H5N Ph II - immunogenic PRE- and CLINICAL STUDIES
3 WHAT HAS HAPPENED SINCE THE LAST MEETING in 0 0 assessments Desk review (reports, presentations, publications) Assessment visits (9 sites Oct-Dec 0) Assessment process: Advance uestionnaire Site visit with expert teams uestionnaire covering: Overall plans National plans Current vaccines prod Staffing and structure Production (process) Filling Facility A/C SOPs Training needs National regulatory process Product approval requirements Marketing/business details Budgetary needs Rsk analysis
4 WHAT HAS HAPPENED SINCE THE LAST MEETING in 0 -year workplans developed jointly with manufacturers, based on the 0 assessments New -year Cooperative Agreement with BARDA Collaboration with OGA-CDC new grants issued Workshop on Enhancing Communication around Influenza Vaccination (June 0, Atlanta) Initiated work on conditions for sustainability
5 06 TARGETS Company / Country Vaccine Late stage** Licensed*** BCHT China Seasonal LAIV Biofarma - Indonesia Seasonal Adjuvanted Pandemic [] Biovac South Africa Seasonal* Adjuvanted pandemic* Birmex Mexico Seasonal* Adjuvanted pandemic* Butantan Brazil Adjuvanted pandemic Cantacuzino - Romania Seasonal Adjuvanted pandemic GPO - Thailand Pandemic LAIV (H5) Seasonal LAIV/IIV IVAC - Viet Nam Pandemic (whole virion) Seasonal (split) SII - India Seasonal LAIV (egg) P? Seasonal LAIV Tissue Culture Torlak - Serbia Seasonal (split) Pandemic (whole virion) 7 Fill-finish; ** includes vaccines in late stage clinical trials or regulatory dossier submitted; *** For pandemic vaccines outside of a pandemic, licensure = mock dossiers or other tentative approval; 5
6 06 TARGETS Total pandemic production capacity at least 600 million Table of maximum current and predicted pandemic capacity by 06. Company Current Predicted* Note Birmex 0 0** Based on 5ug monovalent dose Butantan 0 0 Based on adjuvanted7.5ug dose vaccine Cantacuzino 9 6 Base on improved yields and adjuvanted 7.5ug dose Torlak 0 6 Biovac 0 ** Based on target 8M seasonal supply. SII 0 50** Based on submission TC LAIV and planned scale-up. GPO.5 0** LAIV IVAC 0 ** Biofarma 0. 6 Based on facility completion and adjuvant approval BCHT 0 90** Based on strain-change approval Green Cross Has adjuvant technology, approved adjuvanted vaccine. Total * to make estimations of predicted capacity we count vaccines that are licensed and also those that are in late stage development; ** unless company has dose sparing technology approved or submitted for approval, we assume a dose of 5ug HA or a 0 7 PFU LAIV as experienced with HN, enabling a conversion factor of over the maximum annual seasonal capacity. 6
7 H7N9 grants for H7N9 development BUTANTAN, Inactivated to SII and IEM, LAIV to Bio Farma From Virology Down Under and Dr. Ian M Mackay other manufacturers working on H7N9 (IVAC, BCHT) Barriers: Reagents a very long wait Ferret studies: costs, lab, availability of animals WHO CONDUCTING COORDINATED FERRET STUDIES 7
8 Meeting our targets A lot of progress has been made >00 million pandemic vaccine capacity already. A lot still needs to be made 0-06 To bring candidates to approval, and To add another 00 million doses pandemic capacity Challenges Approval pathways for both seasonal and pandemic Sustainability 8
9 Animal studies Activity Preclinical testing Preclinical study Challenge in ferrets Non-clinical mice study Toxicology & ferret studies. Preclinical immunogenicity Preclinical toxicology Repeated dose toxicity Developmental toxicity Immunogenicity study Single dose toxicity Immunogenicity Preclin immunogenicity (mouse) Toxicology (rat) Toxicology (mouse/rat) Ferret challenge (conducted by WHO) Preclinical immunogenicity Preclinical toxicology Immunogenicity (mice) Toxicology (rat) Ferret challenge A S O N D J F M A M J J A S O N D J F M A M J J A S O N D J F M A M J J A S O N D x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x 9
10 Clinical Trials Activity I II I II I II I/III I Prime-Boost I /II I/III I/III I/III I A S O N D J F M A M J J A S O N D J F M A M J J A S O N D J F M A M J J A S O N D x x x x x x x x x x x x x x x x x x 0
11 Support to manufacturers WHO technical support will continue Technical advice, Visits by TAG and consultants, Interactions with MoH In collaboration with PATH Particular focus on support for preclinical and clinical development Study Protocol Templates being developed Workshop for manufacturers and NRAs the design, conduct and regulatory review of non-clinical and clinical studies in support of initial vaccine approval, annual strain change, process modification, and prequalification (tentatively end June/early July)
12 Maintaining the gains Sustainability of the capacity that you are establishing needs to be addressed. The HHS/WHO Workshop Series has allowed the stakeholders to comprehensively examine the different factors and drivers involved. You will hear tomorrow how the knowledge that was gained will be used to move this agenda forward.
Meeting with international partners on prospects for influenza vaccine technology transfer to developing countries
WHO/IVB/09.06 ORIGINAL: ENGLISH Meeting with international partners on prospects for influenza vaccine technology transfer to developing countries 27 28 November 2008 Pune, Maharashtra, India Immunization,
More informationPandemic Influenza Vaccines: Lessons Learned from the H1N1 Influenza Pandemic
Pandemic Influenza Vaccines: Lessons Learned from the H1N1 Influenza Pandemic Nancy J. Cox, Ph.D. Director, Influenza Division Director WHO Collaborating Center for Influenza NCIRD, Centers for Disease
More informationHSA Consumer Guide. Understanding Vaccines, Vaccine Development and Production. www.hsa.gov.sg November 2009. How a Vaccine Works.
November 2009 Understanding Vaccines, Vaccine Development and Production Vaccines, in general, help protect people from harmful infections before they come in contact with the disease. Vaccines may also
More informationInventory Management Tracking, Distribution and Delivery
Inventory Management Tracking, Distribution and Delivery Ben Erickson Public Health Analyst Office of Public Health Preparedness and Response Division of Strategic National Stockpile Agenda Inventory Management
More informationVaccines: Poised To Deliver Significant Growth in Emerging Markets Citi Vaccine Seminar Pierre Morgon
March 23, 2011 Vaccines: Poised To Deliver Significant Growth in Emerging Markets Citi Vaccine Seminar Pierre Morgon Vice President, Franchise & Global Marketing Operations Sanofi Pasteur London Forward
More informationOpportunities for Emerging Vaccine Markets
Opportunities for Emerging Vaccine Markets Dr. Suresh Jadhav Executive Director Serum Institute of Limited Maharashtra,, 411028 ssj@seruminstitute.com 12 13 March 2014, Brussels Outline Immunization landscape
More informationOverview of Phase 1 Oncology Trials of Biologic Therapeutics
Overview of Phase 1 Oncology Trials of Biologic Therapeutics Susan Jerian, MD ONCORD, Inc. February 28, 2008 February 28, 2008 Phase 1 1 Assumptions and Ground Rules The goal is regulatory approval of
More informationINSTITUTO BUTANTAN. 800.000 m 2
NIT do INSTITUTO BUTANTAN 1901 Established to produce serum against the bubonic plague Vital Brazil, first director, investigated antivenoms against snake bites 800.000 m 2 INSTITUTO BUTANTAN 23 scientific
More informationFAST TRACK DEVELOPMENT OF EBOLA VACCINES: FDA REGULATORY PERSPECTIVE
FAST TRACK DEVELOPMENT OF EBOLA VACCINES: FDA REGULATORY PERSPECTIVE Marion Gruber, Ph.D. Director Office of Vaccines Research & Review Center for Biologics Evaluation and Research US Food and Drug Administration
More informationGrand Challenge: Innovations in Vaccine Manufacturing for Global Markets FAQ
Grand Challenge: Innovations in Vaccine Manufacturing for Global Markets FAQ Grant Objectives Is $0.15/dose cost a per-vaccine target or per-disease target? In other words, can pentavalent vaccine come
More informationAdjuvant Development for IPV. Martin Friede Ph.D. Initiative for Vaccine Research
Adjuvant Development for IPV Martin Friede Ph.D. Initiative for Vaccine Research Role of adjuvants in vaccine development Enable subunit antigens to induce protective immune response Achieve protective
More informationOverview of WHO revised vaccine prequalification procedure
Overview of WHO revised vaccine prequalification procedure Carmen Rodriguez WHO/IVB/QSS Vaccine Industry Consultation meeting 25-26 January 2012 UNICEF SD Copenhagen Purpose of WHO vaccines prequalification
More informationDevelopment of an Influenza Risk Assessment Tool
Development of an Influenza Risk Assessment Tool Susan C. Trock 1, Stephen A. Burke 2 & Nancy J. Cox 1 1 Influenza Division, NCIRD, CDC 2 Battelle Atlanta Analytical Services, Atlanta, GA Foreign & Emerging
More informationSession 4: Attracting Investments and Generating Revenue Theory, Practice and Existing Business Models
Session 4: Attracting Investments and Generating Revenue Theory, Practice and Existing Business Models Case studies How does flu differ from other vaccines and how this affects marketing? Bio Farma: government
More informationH1N1 Vaccine Implementation Overview. Carol Friedman, D.O. Vaccine Implementation Team CDC
H1N1 Vaccine Implementation Overview Carol Friedman, D.O. Vaccine Implementation Team CDC 1 Laboratory-confirmed cases by age group novel influenza A(H1N1) 24 JUL 2009 (n=43,771) 25000 20000 Percentages
More informationAchieving Regulatory Success: Areas of focus for biotechnology companies. Michael J. Schlosser, PhD, DABT April 21, 2013
Achieving Regulatory Success: Areas of focus for biotechnology companies Michael J. Schlosser, PhD, DABT April 21, 2013 Regulatory Success Outline Regulatory Initiatives Regulatory Science Pre-Regulatory
More informationGUIDELINES ON STABILITY EVALUATION OF VACCINES
ENGLISH ONLY GUIDELINES ON STABILITY EVALUATION OF VACCINES World Health Organization 2006 All rights reserved. Publications of the World Health Organization can be obtained from WHO Press, World Health
More informationGeneral presentation
Cantacuzino National Institute of Research-Development for Microbiology and Immunology General presentation Cantacuzino National Institute of Research-Development for Microbiology and Immunology (NIRDMIC)
More informationFORM 6-K. SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549
FORM 6-K SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of April, 2009 Commission
More informationFOR INFORMATION CONTACT:
NEWS RELEASE FOR INFORMATION CONTACT: Caroline Calderone Baisley Deborah C. Travers Director of Health Director of Family Health Tel [203] 622-7836 Tel [203] 622-7854 September 10, 2014 For Immediate Release
More informationSabin-IPV Development
Sabin-IPV Development 9th WHO-UNICEF Informal Consultation with OPV & IPV Manufacturers & NRAs 02 December 2010, Geneva Wilfried Bakker 02 December 2010 WAM Bakker - Sabin-IPV Development 1 Contents Presentation
More informationThe Cell Therapy Catapult
The Cell Therapy Catapult Keith Thompson CEO January 29 2013 info@ct.catapult.org.uk Catapult is a Technology Strategy Board programme The Launch of Catapults Hauser 2 Hauser Report Creating new manufacturing
More informationSWINE FLU: FROM CONTAINMENT TO TREATMENT
SWINE FLU: FROM CONTAINMENT TO TREATMENT SWINE FLU: FROM CONTAINMENT TO TREATMENT INTRODUCTION As Swine Flu spreads and more people start to catch it, it makes sense to move from intensive efforts to contain
More informationsteps were taken. Science-based arguments to support this statement.
The European Scientific Working group on Influenza A(H1N1) pandemic: the right steps were taken. Science-based arguments to support this statement. Prof. Ab Osterhaus, Erasmus MC Rotterdam Prof. Peter
More informationVaccine Production Strategies: Ensuring Alignment and Sustainability
Vaccine Production Strategies: Ensuring Alignment and Sustainability Second WHO Consultation on Global Action Plan for Influenza Vaccines (GAP-II) Robert W Malone, MD, MS Consulting, Vaccines and Biologicals
More informationMINISTRY OF HEALTH PANDEMIC INFLUENZA A / H1N1 2009 VACCINE FREQUENTLY ASKED QUESTIONS
Government of the Republic of Trinidad and Tobago MINISTRY OF HEALTH PANDEMIC INFLUENZA A / H1N1 2009 VACCINE FREQUENTLY ASKED QUESTIONS Influenza vaccines are one of the most effective ways to protect
More informationA Human Designer cell Line Providing a Pandemic Proof Platform for the Manufacturing of Safe Influenza Vaccines
PER.C6 A Human Designer cell Line Providing a Pandemic Proof Platform for the Manufacturing of Safe Influenza Vaccines Fons March 26, 1918-1919 Flu Pandemic ~30 MillionDeaths The Devil in Enveloped virions
More informationWorkshop on Business Planning and Partnership Development for Influenza Vaccine Manufacturing in Developing Countries
WHO/HHS joint Workshop on Business Planning and Partnership Development for Influenza Vaccine Manufacturing in Developing Countries Washington, USA, November 2012 Claudia Nannei, World Health Organization
More informationVaccine Development for Developing Countries Regulatory Approach in the European Union
Vaccine Development for Developing Countries Regulatory Approach in the European Union Dr. Manfred G. Haase, Langen, Germany ECI Vaccine Technology II, June 1-6, 2008, Albufeira, Portugal 1 Regulation
More informationExperiences with Live Attenuated Influenza Vaccine Trials in Thailand and Future Plan
Experiences with Live Attenuated Influenza Vaccine Trials in Thailand and Future Plan Punnee Pitisuttithum, MBBS,DTM&H,FRCPT Vaccine Trial Center,Faculty of Tropical Medicine, Mahidol University For MOPH,CDC,MU,Geneva
More informationPreparing for the consequences of a swine flu pandemic
Preparing for the consequences of a swine flu pandemic What CIGNA is Doing To help ensure the health and well-being of the individuals we serve, CIGNA is implementing its action plan to prepare for the
More informationVaccination policy, vaccine development and manufacturing in Japan. Yoichiro Kino, Ph.D Executive Managing Director Kaketsuken
Vaccination policy, vaccine development and manufacturing in Japan Yoichiro Kino, Ph.D Executive Managing Director Kaketsuken Background of KAKETSUKEN Organization Name The ChemoSeroTherapeutic Research
More informationRoles & Responsibilities of the Sponsor
Roles & Responsibilities of the Sponsor Developed by Center for Cancer Research, National Cancer Institute, NIH Endorsed by the CTN SIG Leadership Group Objectives Funding for clinical research comes from
More informationFee-for-service cores for Investigational New Drug enabling studies
UC DAVIS INSTITUTE FOR REGENERATIVE CURES Fee-for-service cores for Investigational New Drug enabling studies Pipeline pathway at UC Davis Institute for Regenerative Cures Basic Research Proof of Concept
More informationDevelopment of MenAfriVac in India: an example of efficient technology transfer to develop a needed vaccine
Development of MenAfriVac in India: an example of efficient technology transfer to develop a needed vaccine Workshop on Technology Transfer WHO HQ, November 30th December 1st, 2010 Jean-Marie Préaud PATH
More informationAVIAN INFLUENZA. The pandemic influenza clock is ticking. We just don t know what time it is. Laurene Mascola, MD, MPH, FAAP
AVIAN INFLUENZA The pandemic influenza clock is ticking. We just don t know what time it is. Laurene Mascola, MD, MPH, FAAP D12:\Avian Flu.ppt No. 1 OUTLINE Background on Influenza A Impact of influenza
More informationDiploma Course on Research & Development of Products to Meet Public Health Needs
Diploma Course on Research & Development of Products to Meet Public Health Needs Organized by Nagasaki University, Japan and Faculty of Allied Health Sciences, Thammasat University, in cooperation with
More informationNon-clinical development of biologics
Aurigon Life Science GmbH Non-clinical development of biologics Requirements, challenges and case studies Committed to Life. Sigrid Messemer vet. med. M4 Seminar March 10 th 2014 Aurigon - your full service
More informationNRA FUNCTION IN CONTROLLING VACCINES IN CLINICAL TRIAL AND MARKETING AUTHORIZATION INDONESIA 2013 DVI MEETING 9 11 APRIL 2013 1
NRA FUNCTION IN CONTROLLING VACCINES IN CLINICAL TRIAL AND MARKETING AUTHORIZATION INDONESIA 2013 DVI MEETING 9 11 APRIL 2013 1 2 The National Agency of Drug and Food Control (NA-DFC) is a non departmental
More informationGuidelines on the nonclinical evaluation of vaccine adjuvants and adjuvanted vaccines
FINAL ENGLISH ONLY Guidelines on the nonclinical evaluation of vaccine adjuvants and adjuvanted vaccines World Health Organization 2013 All rights reserved. Publications of the World Health Organization
More informationFacilitating Economic Integration in Asia-Pacific through Aid for Trade. 23 April 2014 // Tunis Mia Mikic Teemu Alexander Puutio
Facilitating Economic Integration in Asia-Pacific through Aid for Trade 23 April 2014 // Tunis Mia Mikic Teemu Alexander Puutio ODA finally on the rebound Globally development aid rose by 6.1% in real
More informationHealthcare Personnel Safety Component. Healthcare Personnel Vaccination Module Influenza Vaccination Summary
Healthcare Personnel Safety Component Healthcare Personnel Vaccination Module Influenza Vaccination Summary Acute Care Facilities: 2015-2016 Influenza Season National Center for Emerging and Zoonotic Infectious
More information[NAME OF NATIONAL REGULATORY AUTHORITY] PROCEDURE FOR SUBMISSION CLINICAL TRIAL APPLICATIONS VACCINES AND BIOLOGICALS [COUNTRY]
[TEMPLATE] [NAME OF NATIONAL REGULATORY AUTHORITY] PROCEDURE FOR SUBMISSION OF CLINICAL TRIAL APPLICATIONS OF VACCINES AND BIOLOGICALS IN [COUNTRY] 1of 19 General Procedures for clinical trial applications
More informationBasic Overview of Preclinical Toxicology Animal Models
Basic Overview of Preclinical Toxicology Animal Models Charles D. Hebert, Ph.D., D.A.B.T. December 5, 2013 Outline Background In Vitro Toxicology In Vivo Toxicology Animal Models What is Toxicology? Background
More informationDuring the course of this presentation, data from certain clinical studies may be shown. These studies were sponsored independently by Generex.
GENEREX BIOTECHNOLOGY 2009 Annual General Meeting July 30, 2009 Forward Looking Statements During the course of this presentation, it is possible that statements that could be construed as forward-looking
More informationNOVAVAX INC FORM 424B5. (Prospectus filed pursuant to Rule 424(b)(5)) Filed 03/26/15
NOVAVAX INC FORM 424B5 (Prospectus filed pursuant to Rule 424(b)(5)) Filed 03/26/15 Address 20 FIRSTFIELD ROAD GAITHERSBURG, MD 20878 Telephone 240-268-2000 CIK 0001000694 Symbol NVAX SIC Code 2836 - Biological
More informationAn Introduction to Valuations
An Introduction to Valuations PREPARED FOR ROCKY MOUNTAIN BIOBOOSTER MAY 9 TH, 2012 An ICON plc Company Agenda Introductions Valuation methods When is a valuation appropriate? How do you maximize your
More informationGLP vs GMP vs GCP Dominique Pifat, Ph.D., MBA The Biologics Consulting Group dpifat@bcg-usa.com
GLP vs GMP vs GCP Dominique Pifat, Ph.D., MBA The Biologics Consulting Group dpifat@bcg-usa.com Common Misconception Good Laboratory Practices 1) A quality system concerned with the organizational process
More informationKvartalets)informationsbrev)till)aktieägarna)från)Protein)Sciences)
! M Mertiva!! Pressmeddelande!den!24!september!2015! Kvartalets)informationsbrev)till)aktieägarna)från)Protein)Sciences) Protein(Sciences(Corporation((Protein(Sciences)(har(distribuerat(ett(informationsbrev(till(sina(
More informationRecommended Dose Volumes for Common Laboratory Animals IQ 3Rs Leadership Group - Contract Research Organization Working Group
NOTE: This document includes dose volume guidelines that have been researched and published as well as standards that have gained acceptance through empirical use across multiple members of the IQ 3Rs
More informationAn Analysis of Global Trade in Terephthalic Acid and its Salts
Page 1 12/22/2014 An Analysis of Global Trade in Terephthalic Acid and its Salts The paper summarises the results of an analysis of global trade in Terephthalic Acid. Global trade is obtained by collating
More informationswine flu vaccination:
swine flu vaccination: what you need to know Flu. Protect yourself and others. Contents What is swine flu?............... 3 About the swine flu vaccine....... 4 What else do I need to know?...... 8 What
More informationInstitutions Type Activity
Sıra Recipient Party Description Contributing Party Institutions Type Activity Amount (millions) Currency Report Implementation Period 1 Turkey The training for optimal power generation for peak demand
More informationPlanning for Pandemic Flu. pandemic flu table-top exercise
Planning for Pandemic Flu Lawrence Dickson - University of Edinburgh Background Previous phase of health and safety management audit programme raised topic of Business Continuity Management Limited ability
More informationInvestor Presentation. December 2012 TSX: MDG OTCQX: MDCGF
Investor Presentation December 2012 TSX: MDG OTCQX: MDCGF Forward-Looking Statements and Disclaimers This presentation contains forward-looking information and statements which constitute forwardlooking
More informationThe public health risk of influenza in pigs recent insights, key knowledge gaps
The public health risk of influenza in pigs recent insights, key knowledge gaps Prof. Kristien Van Reeth Laboratory of Virology, Faculty of Veterinary Medicine, Ghent University, Belgium H1N1, H3N2 and
More informationGfK PURCHASING POWER INTERNATIONAL
GfK PURCHASING POWER INTERNATIONAL 1 Agenda 1. Europe 3 2. Americas 45 3. Asia & Near East 54 4. Afrika 66 5. Australia 68 6. Overview of countries and available levels 70 2 2 EUROPE 4 GfK
More informationChallenges in the Regulation of Pediatric Clinical Trials
Challenges in the Regulation of Pediatric Clinical Trials Wilson W. Bryan, M.D. FDA / CBER / OCTGT wilson.bryan@fda.hhs.gov National Institutes of Health Recombinant DNA Advisory Committee (RAC) Meeting
More informationPDP Funders Group Briefing Paper 3. 1. Background. 2. Methods
PRODUCT DEVELOPMENT PARTNERSHIPS (PDPS): WORKING TOGETHER: COLLABORATIONS BETWEEN PDPS AND PHARMACEUTICAL BIOTECHNOLOGY COMPANIES BASED IN EMERGING AND DEVELOPING ECONOMIES 1. Background Product Development
More informationExpanded Programme on Immunization
Expanded Programme on Immunization Expanded Programme on Immunization has been delivered the immunization services to the targeted children of under one year old child and pregnant women. Currently total
More informationRegulatory Pathways for Licensure and Use of Ebola Virus Vaccines During the Current Outbreak FDA Perspective
Regulatory Pathways for Licensure and Use of Ebola Virus Vaccines During the Current Outbreak FDA Perspective Office of Vaccines Research and Review Center for Biologics Evaluation and Research U.S. Food
More informationUS Perspective on the Regulatory Assessment of Benefit-Risk of Vaccines
US Perspective on the Regulatory Assessment of Benefit-Risk of Vaccines Norman W. Baylor Biologics Consulting Group, Inc. 23-25 June 2014 Foundation Merieux Conference Center OUTLINE OF PRESENTATION Introduction
More informationH1N1 Vaccine Deployment and Vaccination update
H1N1 Vaccine Deployment and Vaccination update Outline Donor Commitments Vaccine Prequalification Country Preparedness Vaccine Deliveries Vaccine utilization and coverage Some lessons learned 2 H1N1 Pandemic
More informationUpdating the Vaccine Injury Table: Guillain-Barré Syndrome (GBS) and Seasonal Influenza Vaccines
Updating the Vaccine Injury Table: Guillain-Barré Syndrome (GBS) and Seasonal Influenza Vaccines Ahmed Calvo, M.D., M.P.H. Medical Officer, National Vaccine Injury Compensation Program (VICP) Advisory
More informationThe AVAREF joint review process of Ebola clinical trial applications
The AVAREF joint review process of Ebola clinical trial applications Dr Matthias Stahl, Regulation, Ebola R&D Team 1 Background WHO convened the 9 th annual meeting of the African Vaccine Regulatory Forum
More informationECDC SURVEILLANCE REPORT
ECDC SURVEILLANCE REPORT Pandemic (H1N1) 2009 Weekly report: Individual case reports EU/EEA countries 31 July 2009 Summary The pandemic A(H1N1) 2009 is still spreading despite the fact that the regular
More informationModule Three. Risk Assessment
Module Three Risk Assessment 136 Module Three Introduction to Risk Assessment Time Allotted: 90 Minutes Objectives: Upon completion of this module, the learner will be able to # Define and understand the
More informationInfluenza Risk Assessment Tool. Jacqueline M. Katz, PhD Deputy Director (acting), Influenza Division Centers for Disease Control and Prevention
Influenza Risk Assessment Tool Jacqueline M. Katz, PhD Deputy Director (acting), Influenza Division Centers for Disease Control and Prevention Influenza Risk Assessment Tool (IRAT) A global public health
More informationBiopharmaceutical Process Evaluated for Viral Clearance
Authored by S. Steve Zhou, Ph.D. Microbac Laboratories, Inc., Microbiotest Division The purpose of Viral Clearance evaluation is to assess the capability of a manufacturing production process to inactivate
More informationACCESS TO THE SEASONAL FLU VACCINE IN CANADA. How the flu shot makes its way from the laboratory to the doctor s office.
ACCESS TO THE SEASONAL FLU VACCINE IN CANADA How the flu shot makes its way from the laboratory to the doctor s office. Health Canada is the federal department responsible for helping Canadians maintain
More informationm 4 Biobank Alliance & m 4 Trial Service Center
m 4 Biobank Alliance & m 4 Trial Service Center Services & Consulting in (non-)clinical development www.m4.de m 4 Biobank Alliance Central Access to High Quality Human Biospecimens for R&D The m 4 Biobank
More informationPREPARING FOR A PANDEMIC. Lessons from the Past Plans for the Present and Future
PREPARING FOR A PANDEMIC Lessons from the Past Plans for the Present and Future Pandemics Are Inevitable TM And their impact can be devastating 1918 Spanish Flu 20-100 million deaths worldwide 600,000
More informationCatching the Flu: A Photo Essay
May 2006 Catching the Flu: A Photo Essay As it tests a new way of making vaccines, TechnoVax is targeting the deadly 1918 flu virus. By Stephan Herrera (MIT Technology Review) Jose Galarza is the CEO of
More informationCODE: E.003 Financial Services BUDGET AND BUSINESS PLANNING POLICY. 1.2 The essential activities covered by this policy include:
BUDGET AND BUSINESS PLANNING POLICY CONTENTS 1.1 Budget and business planning is undertaken to support strategic planning and decision-making and to serve accountability by enabling administration to plan
More informationCurrent status of dengue vaccine development
Current status of dengue vaccine development John T. Roehrig, Ph.D. Distinguished Consultant and Research Microbiologist SAGE/Immunization Meeting April 2013 National Center for Emerging and Zoonotic Infectious
More informationPandemic influenza preparedness Framework. for the sharing of influenza viruses and access to vaccines and other benefits
Pandemic influenza preparedness Framework for the sharing of influenza viruses and access to vaccines and other benefits Pandemic influenza preparedness Framework for the sharing of influenza viruses
More informationBT Premium Event Call and Web Rate Card
BT Managed Event and BT Self-Managed Event (also referred to as Express, Plus and Premium) Conference Bridge and Call for Booked Audio Conferencing Services will comprise the following for each phone-conference:
More informationCCAC Animal Data Report
2013 CCAC Animal Data Report Canadian Council on Animal Care Conseil canadien de protection des animaux ACKNOWLEDGMENTS The CCAC extends its sincere thanks to all those responsible for submitting annual
More informationInfluenza and Pandemic Flu Guidelines
Influenza and Pandemic Flu Guidelines Introduction Pandemic flu is a form of influenza that spreads rapidly to affect most countries and regions around the world. Unlike the 'ordinary' flu that occurs
More informationEmergency Use Assessment and Listing Procedure (EUAL) for candidate vaccines for use in the context of a public health emergency
Emergency Use Assessment and Listing Procedure (EUAL) for candidate vaccines for use in the context of a public health emergency Introduction The 2014 Ebola outbreak is the largest Ebola epidemic in history,
More informationThree Experience Pillars of Personal Health Eric Dishman Intel Fellow & General Manager, Intel Health and Life Sciences Group
Three Experience Pillars of Personal Health Eric Dishman Intel Fellow & General Manager, Intel Health and Life Sciences Group Entrepreneurial caregiver, patient, scientist 2 Studied history of healthcare
More informationEnveloped Virus Like Particles: Third-generation VLPs for the Development of a Broadly Neutralizing Hepatitis C Vaccine
Enveloped Virus Like Particles: Third-generation VLPs for the Development of a Broadly Neutralizing Hepatitis C Vaccine World Vaccine Congress Asia June 2015 Forward-Looking Statement Disclaimer This presentation
More informationI thank them for their openness, transparency, and willingness to work with WHO to address this newly emerging infection.
I N F L U E N Z A - L I K E I L L N E S S O U T B R E A K I N T H E U S A N D M E X I C O T r a n s c r i p t o f G L O B AL T E L E P H O N E N E W S C O N F E R E N C E w i t h D r M a r g a r e t C
More informationSample: Policy for the Administration of Influenza Vaccine Employees in Health Care Settings
Sample: Policy for the Administration of Influenza Vaccine Employees in Health Care Settings 1.0 PURPOSE The purpose of this policy is to minimize transmission of the influenza virus in the workplace by
More informationInfluenza - H1N1 Vaccination Program Questions and Answers. Prepared by
Influenza - H1N1 Vaccination Program Questions and Answers Prepared by Military Vaccine (MILVAX) Agency, Office of The Army Surgeon General, U.S. Army Last Updated: 27 Oct 09 www.vaccines.mil 877-GET-VACC
More informationIIBA Enhanced Certification
Gain Insight IIBA Enhanced Certification May 2016 Certification and Recognition Agenda Stakeholder Engagement Enhanced Certification Framework Next Steps Q&A 2 Stakeholder Engagement Framework & Levels
More informationOffice of Global Affairs and the Global Action Plan for Influenza Vaccines
Office of Global Affairs and the Global Action Plan for Influenza Vaccines Anne Yu, Acting Director Office of Pandemics and Emerging Threats Office of Global Affairs Photo Credit: F. A. Murphy, CDC Our
More informationManufacturing process of biologics
Manufacturing process of biologics K. Ho Afssaps, France 2011 ICH International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use 2011 ICH 1 Disclaimer:
More informationGuide to Fees for Veterinary Products
Guide to Fees for Veterinary Products FIN-G0003-14 04 FEBRUARY 2016 This guide does not purport to be an interpretation of law and/or regulations and is for guidance purposes only. CONTENTS ABBREVIATIONS
More informationKMS-Specialist & Customized Biosimilar Service
KMS-Specialist & Customized Biosimilar Service 1. Polyclonal Antibody Development Service KMS offering a variety of Polyclonal Antibody Services to fit your research and production needs. we develop polyclonal
More informationGuidance for Industry Influenza: Developing Drugs for Treatment and/or Prophylaxis
Guidance for Industry Influenza: Developing Drugs for Treatment and/or Prophylaxis U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER)
More informationClinical and Laboratory Practices Workshops. Helping to improve laboratory skills and the quality of care in resource-limited settings
Clinical and Laboratory Practices Workshops Helping to improve laboratory skills and the quality of care in resource-limited settings BD is committed to collaborating with governmental and non-governmental
More informationH1N1 Flu Vaccine Available to All Virginia Beach City Public Schools Students
V i r g i n i a B e a c h C i t y P u b l i c S c h o o l s apple-a-day F o r O u r F a m i l y o f I n t e r e s t e d C i t i z e n s Special Edition H1N1 Flu Vaccine Available to All Virginia Beach
More informationBCOE-PF1 Pandemic Influenza : Building a Continuity Plan
BCOE-PF1 Pandemic Influenza : Building a Continuity Plan Course Description The continuing risk presented by swine influenza (H1N1) has resulted in organizations taking definitive steps to reduce the impact
More informationAnnex 5. Recommendations to assure the quality, safety and efficacy of tetanus vaccines (adsorbed)
Recommendations to assure the quality, safety and efficacy of tetanus vaccines (adsorbed) Replacement of Annex 2 of WHO Technical Report Series, No. 800, and Annex 5 of WHO Technical Report Series, No.
More informationClinical Data Management Overview
The 2 nd Clinical Data Management Training Clinical Data Management Overview Andrew Taylor ( 安 泰 乐 ), M.S. Head of Clinical Data Management August 30, 2010 Learning Objectives Overview of Process Related
More informationClinical trials in developing countries submitted to EMEA for regulatory purposes
Clinical trials in developing countries submitted to EMEA for regulatory purposes Rome, UNICRI/AIFA December 2008 Hans-Georg Eichler Agenda Challenges EU regulatory requirements for clinical trials Facts
More informationMartin Ensureck: Dr Fukuda:
1 Transcript of virtual press conference with Dr Keiji Fukuda, Assistant Director-General ad Interim for Health Security and Environment, World Health Organization 7 July 2009 Dick Thompson: Welcome to
More informationBio-manufacturing of antigens, antibodies and bioresearch materials
Bio-manufacturing of antigens, antibodies and bioresearch materials Foetal Bovine Serum (FBS) Human AB Serum Chick Embryo Extract (CEE) Custom polyclonal antibody production Custom monoclonal antibody
More information